Logo image of AMTI

APPLIED MOLECULAR TRANSPORT (AMTI) Stock Fundamental Analysis

NASDAQ:AMTI - Nasdaq - US03824M1099 - Common Stock - Currency: USD

0.263  -0.04 (-14.3%)

After market: 0.2629 0 (-0.04%)

Fundamental Rating

2

AMTI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. While AMTI seems to be doing ok healthwise, there are quite some concerns on its profitability. AMTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AMTI has reported negative net income.
In the past year AMTI has reported a negative cash flow from operations.
In the past 5 years AMTI always reported negative net income.
In the past 5 years AMTI always reported negative operating cash flow.
AMTI Yearly Net Income VS EBIT VS OCF VS FCFAMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

AMTI has a Return On Assets of -373.95%. This is amonst the worse of the industry: AMTI underperforms 97.30% of its industry peers.
AMTI has a worse Return On Equity (-461.67%) than 80.61% of its industry peers.
Industry RankSector Rank
ROA -373.95%
ROE -461.67%
ROIC N/A
ROA(3y)-70.66%
ROA(5y)-82.71%
ROE(3y)-106.54%
ROE(5y)-110.95%
ROIC(3y)N/A
ROIC(5y)N/A
AMTI Yearly ROA, ROE, ROICAMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

AMTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMTI Yearly Profit, Operating, Gross MarginsAMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

AMTI has more shares outstanding than it did 1 year ago.
AMTI has a worse debt/assets ratio than last year.
AMTI Yearly Shares OutstandingAMTI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
AMTI Yearly Total Debt VS Total AssetsAMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

AMTI has an Altman-Z score of -36.49. This is a bad value and indicates that AMTI is not financially healthy and even has some risk of bankruptcy.
AMTI has a Altman-Z score of -36.49. This is amonst the worse of the industry: AMTI underperforms 94.94% of its industry peers.
AMTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -36.49
ROIC/WACCN/A
WACCN/A
AMTI Yearly LT Debt VS Equity VS FCFAMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.95 indicates that AMTI has no problem at all paying its short term obligations.
The Current ratio of AMTI (4.95) is comparable to the rest of the industry.
A Quick Ratio of 4.95 indicates that AMTI has no problem at all paying its short term obligations.
With a Quick ratio value of 4.95, AMTI perfoms like the industry average, outperforming 51.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.95
Quick Ratio 4.95
AMTI Yearly Current Assets VS Current LiabilitesAMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.09% over the past year.
EPS 1Y (TTM)45.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AMTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.28%
EPS Next 2Y32.75%
EPS Next 3Y14.38%
EPS Next 5Y12.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMTI Yearly Revenue VS EstimatesAMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M
AMTI Yearly EPS VS EstimatesAMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMTI Price Earnings VS Forward Price EarningsAMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMTI Per share dataAMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

AMTI's earnings are expected to grow with 14.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.75%
EPS Next 3Y14.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED MOLECULAR TRANSPORT

NASDAQ:AMTI (12/26/2023, 8:00:01 PM)

After market: 0.2629 0 (-0.04%)

0.263

-0.04 (-14.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)03-07 2024-03-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners1.85%
Ins Owner Change0%
Market Cap11.01M
Analysts43.33
Price Target1.02 (287.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-44.68%
Min EPS beat(2)-156.02%
Max EPS beat(2)66.67%
EPS beat(4)2
Avg EPS beat(4)-25.3%
Min EPS beat(4)-156.02%
Max EPS beat(4)66.67%
EPS beat(8)3
Avg EPS beat(8)-21.97%
EPS beat(12)5
Avg EPS beat(12)-11.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.43
OCFYN/A
SpS0
BVpS0.39
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -373.95%
ROE -461.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.66%
ROA(5y)-82.71%
ROE(3y)-106.54%
ROE(5y)-110.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.95
Quick Ratio 4.95
Altman-Z -36.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)159.65%
Cap/Depr(5y)173.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.85%
EPS Next Y70.28%
EPS Next 2Y32.75%
EPS Next 3Y14.38%
EPS Next 5Y12.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.85%
OCF growth 3YN/A
OCF growth 5YN/A